2022 World Conference on Lung Cancer (ePosters)-EP02.02-009. Stereotactic Body Radiotherapy for Primary and Metastatic Lung Cancer, Cyberknife-M6 Experience

EP02.02-009. Stereotactic Body Radiotherapy for Primary and Metastatic Lung Cancer, Cyberknife-M6 Experience

Pdf Summary

This study evaluated the efficacy and outcomes of stereotactic body radiotherapy (SBRT) using Cyberknife-M6 (CK-M6) in patients with inoperable primary or metastatic lung cancer. The study aimed to assess local control (LC), survival, and toxicity. A total of 21 patients with 23 lesions were treated between 2019 and 2020. The treatment planning involved obtaining a 4D-CT scan and selecting the appropriate tracking modality based on target visibility. The CK-M6 was used for noninvasive SBRT, and the median treatment time was 26 minutes. The study found that a 2 mm clinical target volume (CTV) margin was effective in reducing lung dose without exceeding dose limits or causing G3 pulmonary toxicity. The results showed 85.7% local control with a median survival of 26 months. However, the study had limitations in terms of its heterogeneous population and small sample size. Despite these limitations, the study demonstrated the effectiveness, safety, and comfort of CK-M6-based SBRT in lung cancer treatment. In terms of survival analysis, age, complete response, and target type were found to be significant factors in overall survival (OS) and age was significant in local recurrence-free survival (LRFS). Dosimetric parameters were reported, including prescription dose, ITV and PTV volume, conformity index, and lung dose metrics. In conclusion, this study provides evidence to support the use of CK-M6-based SBRT as an efficient and noninvasive treatment option for inoperable primary or metastatic lung cancer, with promising local control and survival outcomes. Further research with a larger patient population is needed to validate these findings.

Asset Subtitle

Sureyya Sarihan

Meta Tag

Speaker Sureyya Sarihan

Topic Early Stage Non-small Cell Lung Cancer - Radiotherapy

Keywords

SBRT

Cyberknife-M6

lung cancer

local control

survival

toxicity

treatment planning

clinical target volume

pulmonary toxicity

CK-M6-based SBRT